ABSTRACT. Hepcidin prevents absorption of iron from the intestine and inhibits release of iron from macrophages and hepatocytes. For this reason, it seems that high levels of hepcidin are a predisposing factor for anemia in chronic inflammatory conditions such as chronic kidney disease and dialysis patients. This study was designed to determine the role of changes in the level of serum hepcidin in the management of hemodialysis patients. This study included 44 dialysis patients and 44 controls. The hepcidin and pro-hepcidin levels were measured by the enzymelinked immunosorbent assay method. The serum ferritin level was measured by the chemi luminescence method. The mean hepcidin level was 999.3 ± 996.7 ng/mL in the case group and 770.4 ± 815.9 ng/mL in the control group (P = 0.25). The mean pro-hepcidin level was, respec tively, 186.1 ± 220.3 pg/mL and 150.87 ± 207.7 pg/mL, in the case group and control groups (P = 0.45). The mean (standard deviation) ferritin level was 816.4 ± 379.4 ng/mL in the case group and 193 ± 171.8 ng/mL in the control group (P <0.001). In the case group, the correlation between serum ferritin and hepcidin was not significant (r = 0.6, P = 0.08). Also, there was no significant correlation between serum ferritin and pro-hepcidin levels (r = 0.6, P = 0.08). A positive corre lation was seen between pro-hepcidin and hepcidin levels (r = 0.92, P <0.01). In this study, the results showed that the serum hepcidin levels are high in dialysis patients and that there was no correlation with the serum ferritin levels.
Introduction
Dr. Hamidreza Joshaghani, Chronic renal failure (CRF) is a severe debiSchool of Paramedicine, Falsafi Building, litating disease and is associated with many Hirkan Boulevard, Gorgan, Iran systemic complications, and anemia is one of E-mail: joshaghani@goums.ac.ir them. 1 Renal anemia is considered as a form of anemia of chronic diseases that is often of the normochromic normocytic type. Anemia of chronic diseases is seen in many diseases associated with inflammation, such as cancer, chronic infections and autoimmune diseases. 2 Anemia is a major factor in many of the symp toms associated with decreased renal function. These complications cause a significant in crease in mortality due to cardiovascular di sease in dialysis patients. 3 The kidneys are the primary site for the synthesis of erythropoietin (EPO) in adults. Interleukin-6 is the most im portant cytokine involved in the production of hepcidin and the inflammatory condition axis of hepcidin-interleukin (IL)-6 is responsible for iron deficiency during inflammation. 4, 5 Hepcidin is a low molecular weight protein that has recently been discovered and plays an important role in iron metabolism. It is a regulator of renal iron homeostasis. 6 Pre-pro hepcidin, with 84 amino acids, is produced in the hepatocytes and is then broken down to 60 amino acid pro-hepcidin that appears in the plasma. 7 Hepcidin prevents the release of iron from the macrophages and decreases iron ab sorption in the intestine. 8 Various physiolo gical and pathological conditions are effective in the synthesis of hepcidin. On the other hand, synthesis of hepcidin increases in infec tions and inflammatory processes. 9 Hepcidin is considered as one of the acute phase proteins. It is believed that this effect can lead to anemia of chronic disease, which is caused by a decrease of circulating iron avai lable for erythropoiesis, despite normal iron stores. 10 The hepcidin level increases in pa tients with CRF and hemodialysis (HD) pa tients. 11, 12 Hepcidin is cleared only in some patients during dialysis. Exactly why this hap pens is not clear yet, but it may be due to differences in the membranes of various dia lyzers, state of kidney function or induction of hepcidin during the process of HD. 6 Hepcidin may be associated with resistance to factors triggering the production of EPO and an imbalance in iron metabolism in CRF patients. In addition, hepcidin can also be discussed as a therapeutic agent as decreasing the levels of hepcidin can lead to improved iron uptake from the intestine and macrophages; thus, anti hepcidin therapy can be a substitute for intra venous iron therapy. 13 The aim of this study was to evaluate the level of pro-hepcidin and hepcidin in patients with CRF on HD.
Materials and Methods
In this study, 44 HD patients and 44 healthy controls were sampled. Before dialysis, 6 mL of blood was taken from each patient and, after separation, the sera were stored in the freezer at -70°C. Subjects with active infection (fever or other evidence of infection) were excluded. The control subjects were healthy individuals with normal serum urea and creatinine. Hep cidin (IBL) and pro-hepcidin (Glory Science) were measured by the enzyme-linked immuno sorbent assay method. The serum ferritin was measured by the luminescence quantitative method (Monobind). To investigate the correlation between diffe rent variables and eliminate confounding va riables in the subjects of the study, we used multivariate analysis (logistic regression). For this purpose, variables that had a P-value <0.2 on univariate analysis were entered into the multivariate analysis. For comparison of the mean of variables that was not normally dis tributed, the Mann-Whitney test was used and for variables that had normal distribution, the Student t-test was used. The chi-square test was used to evaluate the qualitative variables and the t-test was used to compare the quanti tative variables between the two groups. A Pvalue <0.05 was considered significant. This study was performed with the approval of the Research Ethics Committee of the Golestan University of Medical Sciences.
Results
In each of the groups, 54.5% of the parti cipants were male (P = 0.58). 31.8% of the patient group and 27.3% of the control group had age below 50 years (P = 0.41). The mean pro-hepcidin level in the case and control groups was 186.1 ± 220.3 pg/mL and 150.87 ± 207.7 pg/mL, respectively (P = 0.45). The mean hepcidin level in the CRF patients and in the normal controls was 999.3 ± 996.7 ng/mL and 770.4 ± 815.9 ng/mL, respectively (P = 0.25). In CRF patients, the mean pro-hepcidin level was 168.2 ± 226 pg/mL in males and 207.7 ± 216.9 pg/mL in females (P = 0.54) and the mean hepcidin was 816.8 ± 840.6 ng/mL in males and 1218.2 ± 1140.4 ng/mL in females (P = 0.77). In the control group, the mean pro-hepcidin was 123.6 ± 161.5 pg/mL in males and 182.5 ± 252 pg/mL in females (P = 0.84) and the mean hepcidin was702.3 ± 757.2 ng/mL in males and 849.2 ± 893.4 ng/mL in females (P = 0.73) ( Table 1 ). The mean serum ferritin was 816.4 ± 379.4 ng/mL in the case group and 193 ± 171.8 ng/ml in the control group (P (0.001>. In the case group, no significant correlation was ob served between serum ferritin and hepcidin and pro-hepcidin levels (r = 0.6, P = 0.08). Also, in this group, a significant positive cor relation was observed between pro-hepcidin and hepcidin levels (r = 0.92, P <0.01). In the control group, no significant correlation was seen between serum ferritin and hepcidin (r = 0.4, P = 0.14) and pro-hepcidin levels (r = 0.7, P = 0.06). Also, in this group, a significant correlation was seen between pro-hepcidin and hepcidin levels (r = 0.8, P (0.01>. The level of hepcidin had a direct correlation with the dura tion on dialysis in the case group, but it was not significant (r = 0.3, P = 0.06). Also, a di rect correlation was observed between dura tion on dialysis and pro-hepcidin levels (r = 0.3, P = 0.09). On multivariate regression ana lysis of the variables such as age and ferritin, pro-hepcidin and hepcidin levels, the only va riable that was significantly associated with the risk of anemia was ferritin levels (P <0.001).
Discussion
This study was conducted to evaluate the serum levels of hepcidin in HD patients and normal subjects. In our study, the mean pro hepcidin level had no significant difference in the case and control groups. Tomosug et al, in a study in 2006, measured the hepcidin levels in patients with CRF and found that the hepcidin level was approximately two-to three-times higher than in the control group. In contrast, serum levels of β2-microglobulin, which is a low molecular weight protein that is controlled almost totally by glomerular filtra tion, there was a 20-30-times increase in the levels. Thus, glomerular filtration has little effect on hepcidin level that theoretically may explain the presence of an unknown carrier in the circulation for hepcidin, which can cause decreased renal clearance of this molecule. 14 Young et al in a study in 2009 showed that the pro-hepcidin level increases in dialysis pa tients and correlates inversely with the glo merular filtration rate (GFR). However, pro hepcidin has minimal interaction with iron or inflammatory parameters in dialysis patients; also, it seems that pro-hepcidin is an interme diate metabolite and without physiological activity and its level is not associated with the active production of hepcidin. 15 In the study performed by Zaritsky et al in 2009, the serum ferritin level in children with CRF was higher than in adults with CRF. 16 In our study, there was no significant correlation between ferritin and hepcidin and pro-hepcidin levels.
In a study performed by Busbridge et al in patients with inflammatory bowel disease, a direct correlation was reported between ferritin and hepcidin levels. 17 The mismatch of the results may be due to successful HD or small sample size. It is recommended that further studies should be performed with a larger sam ple size and the blood levels of these variables should be compared with the erythrocyte indices. In our study, no significant correlation was seen between duration on dialysis and hepcidin and pro-hepcidin levels. In a study performed by Li et al, the hepcidin level was higher in patients with renal failure and those on HD. 11 Peters et al in their study in 2010 from Holland found that the hepcidin level was higher in patients on chronic HD than in the control group. They also showed that the ferritin level in CRF and HD groups was higher than in the control group and found a significant correlation between hepcidin and ferritin levels. They concluded that the ferritin level is the only predicting factor for hepcidin level. 12 According to studies performed in 2008 and 2010, it seems that the hepcidin level has no correlation with duration of dialysis, but the GFR is an important factor that shows corre lation with the hepcidin level. 6, 12 Abbasi et al reported that the pro-hepcidin level in CRF patients was higher than in the control group. 18 According to a study that was performed in 2011, the hepcidin level did not show a corre lation with sex, race and age. 19 In our study, the mean serum ferritin was significantly higher in the dialysis group than in the control group. In a study performed by Nakanishi et al in 2011, direct and significant correlation was observed between serum ferritin and hepcidin levels. 20 
